¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"group antigens"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
¿µ¹® blood group ÇÑ±Û Ç÷¾×Çü
¼³¸í   
  »ç¶÷ÀÇ ÀûÇ÷±¸ Ç¥¸é¿¡´Â ¿©·¯ °¡Áö Ç׿ø¼ºÀ» °¡Áø ¹°ÁúÀÌ Á¸ÀçÇÑ´Ù. Á鿪ÇÐÀû ¹ÝÀÀÀ» ÀÏÀ¸Å³ ¼ö Àִ ¹°ÁúÀ» Ç¥¸é¿¡ °¡Áö°í ÀÖ´Ù. ±×¸®°í »ç¶÷ÀÇ ÇǼӿ¡´Â À̰Ͱú ¹ÝÀÀÇÒ ¼ö°¡ Àִ Ç×üµµ Á¸ÀçÇÑ´Ù. »ç¶÷ÀÇ Ç÷¾×Àº À̰Ϳ¡ µû¶ó ¸î°¡Áö ÇüÀ¸·Î ºÐ·ùÇÒ ¼ö°¡ ÀÖ°í, À̰ÍÀ» Ç÷¾×ÇüÀ̶ó°í ÇÑ´Ù. Ç÷¾×ÇüÀº ÀûÇ÷±¸ Ç¥¸é¿¡ Àִ ¾î¶² ¹°ÁúÀ» ±âÁØÀ¸·Î ÇÏ´À³Ä¿¡ µû¶ó¼­ ¿©·¯ °¡Áö·Î ºÐ·ùµÉ ¼ö ÀÖ´Ù. ´ëÇ¥ÀûÀΠÇ÷¾×ÇüÀÇ ±¸ºÐ ¹æ¹ý¿¡´Â ABOÇ÷¾×Çü°ú RhÇ÷¾×ÇüÀÌ ÀÖ´Ù.
  
  1. ABO Ç÷¾×Çü
  
  °¡Àå ¸¹ÀÌ »ç¿ëµÇ°í Àִ Ç÷¾×Çü ±¸ºÐ¹ý. ÀûÇ÷±¸ Ç¥¸é¿¡´Â A, BÇüÀÇ µÎ °¡Áö ¹°ÁúÀ» Çϳª, È¤Àº µÑ, ¶Ç´Â Çϳªµµ °¡ÁöÁö ¾ÊÀ» ¼ö°¡ ÀÖ´Ù. ±×¸®°í ÇǼӿ¡´Â À̰Ͱú ¹ÝÀÀÇØ¼­ ÀûÇ÷±¸¸¦ ÆÄ±«Çϰųª ÀÀÁý½Ãų ¼ö Àִ ¹°Áú(Ç×ü)ÀÌ Á¸ÀçÇÑ´Ù. ¹°·Ð ÀÚ½ÅÀÇ ÀûÇ÷±¸°¡ °¡Áö°í Àִ ¹°Áú¿¡ ´ëÇÑ Ç×ü´Â Á¸ÀçÇÏÁö ¾Ê´Â´Ù.
  
  -AÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ AÇ׿ø, Ç÷¾×¼Ó¿¡ B¿¡ ´ëÇÑ Ç×ü
  
  -BÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ BÇ׿ø, Ç÷¾×¼Ó¿¡ A¿¡ ´ëÇÑ Ç×ü
  
  -ABÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ A, BÇ׿ø, Ç÷¾×¼Ó¿¡ A,B¿¡ ´ëÇÑ Ç×ü¸¦ °¡ÁöÁö ¾Ê´Â´Ù.
  
  -OÇü Ç÷¾×Çü£­ÀûÇ÷±¸ Ç¥¸é¿¡ A, BÇ׿ø ¸ðµÎ¸¦ °¡ÁöÁö ¾Ê°í, Ç÷¾×¼Ó¿¡ A, B¿¡ ´ëÇÑ Ç׿øÀ» ¸ðµÎ °¡Áø´Ù.
  
  ´ë°³ À̰ÍÀ» ÀÌ¿ëÇÏ¿© ¼öÇ÷ÀǠŸ´ç¼º ¿©ºÎ¸¦ Á¶»çÇÑ´Ù. ¸¸¾à AÇü Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ÀÇ ÇǸ¦ BÇü Ç÷¾×ÇüÀÇ »ç¶÷¿¡°Ô ¼öÇ÷Çϸé BÇü Ç÷¾×ÇüÀ» °¡Áø ÀÚÀÇ ÇǼӿ¡ Àִ A¿¡ ´ëÇÑ Ç×ü¶§¹®¿¡ µé¾î¿Â AÇüÀÇ ÀûÇ÷±¸´Â ÆÄ±«µÇ°Å³ª, ÀÀÁýÀÌ µÈ´Ù. OÇüÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ÀÇ Ç÷¾×ÀÇ ÀûÇ÷±¸´Â Ç¥¸é¿¡ A, BÀÇ ¾î¶°ÇÑ ¹°Áúµµ °¡Áö°í ÀÖÁö ¾Ê¾Æ¼­ ¾î¶°ÇÑ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷¿¡°Ô ¼öÇ÷ÇØµµ ¹ÝÀÀÀ» ÀÏÀ¸Å°Áö ¾Ê´Â´Ù. À̿͠°°Àº ¿ø¸®·Î ABÇüÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷Àº Ç÷¾×¼Ó¿¡ A, B¿¡ ´ëÇÑ Ç×ü¸¦ ¸ðµÎ °¡Áö°í ÀÖÁö ¾ÊÀ¸¹Ç·Î ¾î¶°ÇÑ Ç÷¾×ÇüÀ̶󵵠¹ÞÀ» ¼ö°¡ ÀÖ´Ù.
  
  2. RhÇ÷¾×Çü
  
  ÀûÇ÷±¸Ç¥¸é¿¡ Àִ D¶ó´Â ¹°ÁúÀ» ±âÁØÀ¸·Î ÇÏ¿© Ç÷¾×ÇüÀ» ³ª´©´Â ¹æ¹ý. ¸¸¾à D¶ó´Â ¹°ÁúÀÌ ÀûÇ÷±¸ÀǠǥ¸é¿¡ Á¸ÀçÇϸé Rh(+), Á¸ÀçÇÏÁö ¾ÊÀ¸¸é Rh(£­)¶ó°í ÇÑ´Ù. ABOÇ÷¾×Çü¿¡¼­¿Í °°ÀÌ Rh(+)Ç÷¾×ÇüÀ» °¡Áö´Â »ç¶÷ÀÇ ÇǼӿ¡´Â D¶ó´Â ¹°Áú¿¡ ´ëÇÑ Ç×ü°¡ Á¸ÀçÇÏÁö ¾ÊÁö¸¸ Rh(£­)Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ÀÇ ÇǼӿ¡´Â D¿¡ ´ëÇÑ Ç×ü°¡ Á¸ÀçÇÑ´Ù. ABOÇ÷¾×Çü°ú ¸¶Âù°¡Áö·Î ¼öÇ÷ÀǠŸ´ç¼ºÀ» °áÁ¤Çϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • T antigens
    TÇ׿ø
  • atomic group
    ¿øÀÚ´Ü
  • ABO blood group system
    ABOÇ÷¾×Çüü°è
  • amino group
    ¾Æ¹Ì³ë±â
  • basic food group
    ±âÃʽÄǰ±º
  • blood group
    Ç÷¾×Çü
  • blood group incompatibility
    Ç÷¾×ÇüºÎÀûÇÕ
  • blood group system
    Ç÷¾×Çüü°è
  • coliform group
    ´ëÀå±Õ±º
  • complementation group
    »óº¸¼ºÁý´Ü
  • control group
    ´ëÁ¶±º
  • determinant group
    °áÁ¤±º
  • diagnosis related group
    Æ÷°ý¼ö°¡Á¦
  • directive group therapy
    Áö½ÃÁý´Ü¿ä¹ý
  • end group
    ¸»´Ü±â
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • group
    ¹«¸®, ±º, Áý´Ü, ¸ðµÒ
  • amino group
    ¾Æ¹Ì³ë±â
  • diagnosis related group
    Æ÷°ý¼ö°¡Á¦
  • high risk group
    °íÀ§Ç豺
  • low risk group
    ÀúÀ§Ç豺
  • self-help group
    ÀÚ°¡µµ¿òÁý´Ü
  • group practice
    Áý´Ü°³¾÷
  • blood group system
    Ç÷¾×Çü±º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ABO blood group system
    ¿¡À̺ñ¿ÀÇ÷¾×Çü±º
  • amino group
    ¾Æ¹Ì³ë±â
  • atomic group
    ¿øÀÚ´Ü
  • group antigen
    ±ºÇ׿ø
  • group audiometry
    Áý´Üû·Â°Ë»ç
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • basic food group
    ±âÃʽÄǰ±º
  • blood group
    Ç÷¾×Çü
  • blood group incompatibility
    Ç÷¾×ÇüºÎÀûÇÕ
  • blood group system
    Ç÷¾×Çü±º
  • blood group specific substance
    Ç÷¾×ÇüƯÀ̹°Áú
  • borderline group
    °æ°è±º
  • coliform group
    ´ëÀå±Õ±º
  • complementation group
    »óº¸¼ºÁý´Ü
  • complementophil group
    º¸Ã¼Ä£È­±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • HLA= human leukocyte antigen ; hist ocompatibility antigens ; tran splan tation antigens
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, ÀιéÇ÷±¸Ç׿ø.
  • HLA= human leukocyte antigen ; histocompatibility antigens ; transplantation anti
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, »ç¶÷¹éÇ÷±¸Ç׿ø.
  • Yka antigens
    YKa Ç׿ø
  • granulocyte-erythrocyte antigens
    °ú¸³±¸ÀûÇ÷±¸Ç׿ø
  • granulocyte-monocyte antigens
    °ú¸³±¸´Ü±¸Ç׿ø
  • granulocyte-monocyte-lymphocyte antigens
    °ú¸³±¸´Ü±¸¸²ÇÁ±¸Ç׿ø
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • granulocyte-specific antigens
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • histocompatibility antigens
    Á¶Á÷ÀûÇÕ Ç׿ø
  • platelet-specific antigens
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • ABO blood group
    ABO Ç÷¾×Çü.
  • ABO blood group system
    ABOÇ÷¾×Çü°è(Åë).
  • ABO blood group=ABO system
    ABO Ç÷¾×Çü
  • Coxsackie group A
    ÄÛ»èŰ A±º.
  • Coxsackie group B
    ÄÛ»èŰ B±º.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • granulocyte-erythrocyte antigens
    °ú¸³±¸ÀûÇ÷±¸Ç׿ø
  • granulocyte-monocyte antigens
    °ú¸³±¸´Ü±¸Ç׿ø
  • granulocyte-monocyte-lymphocyte antigens
    °ú¸³±¸´Ü±¸¸²ÇÁ±¸Ç׿ø
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • granulocyte-specific antigens
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • histocompatibility antigens
    Á¶Á÷ÀûÇÕ Ç׿ø
  • human platelet antigens=HPA
    ÀÎÇ÷¼ÒÆÇÇ׿ø
  • platelet-specific antigens
    Ç÷¼ÒÆÇƯÀÌÇ׿ø
  • amino group
    ¾Æ¹Ì³ë±â(¡­Ðñ).
  • analytic group psychotherapy
    ºÐ¼®Àû Áý´Ü Á¤½ÅÄ¡·á
  • anterior sinus group
    ÀüºÎºñµ¿±º
  • atomic group
    ¿øÀÚ´Ü.
  • audiometry, group
    Áý´Üû·Â°Ë»ç
  • basic food group
    ±âÃʽÄǰ±º(¡­ãÝù¡ÏØ).
  • behavioral group therapy
    Áý´ÜÇൿġ·á(¿ä¹ý)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Group of isogenous chondrocyte
    ¿¬°ñ¼¼Æ÷¹«¸®
    [¿¾ ¿ë¾î] ¿¬°ñ¼¼Æ÷±ºÁý
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • end group spine
    ±ê³¡°¡½Ã
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • carcinoembryonic antigens
    ¾Ï¹è¾ÆÇ׿ø(äßÛÏä´ù÷ê«)
  • class II MHC antigens
    "Á¦ 11 ·ù(×¾) MHC Ç׿ø(ù÷ê«), (ÔÒ) 1-region-associated antigens"
  • Epa antigens
    EPa Ç׿ø(ù÷ê«)
  • H-2 antigens
    H-2 Ç׿ø(ù÷ê«)
  • HLA antigens
    HLA Ç׿ø (ù÷ê«)
  • ABO blood group (type) system
    ABOÇ÷¾×Çü (úìäûúþ) ½Ã½ºÅÛ
  • acetyl group
    ¾Æ¼¼Æ¿±â(Ðñ)
  • acyl group
    ¾Æ½Ç±â(Ðñ)
  • alcoholic hydroxyl group
    ¾ËÄݼº(àõ) ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • aldehyde group
    ¾Ëµ¥ÇÏÀ̵å±â(Ðñ)
  • amino group
    ¾Æ¹Ì³ë±â(Ðñ)
  • angle methyl group
    ¾Þ±Û¸ÞÆ¿±â(Ðñ)
  • aryl group
    ¾Æ¸±±â(Ðñ)
  • azide group
    ¾ÆÀÚÀ̵å±â(Ðñ)
  • azo group
    ¾ÆÁ¶±â(Ðñ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • control group
    ´ëÁ¶±º
  • group file
    ±×·ì È­ÀÏ
  • high risk group
    °íÀ§Çèµµ±º
  • JPEG [=joint photographic expert group]
    JPEG
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CREG Cross REactive Group (of HLA Antigens)
AFP Alpha(¥á) Feto-Protein [HP 1826, 1858, 1859, 2265]
  ; Oncofetal Antigens
 &nbs...
Anti-ENA Anti-Extractable Nuclear Antigens
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
ANA acetylneuraminic acid; American Narcolepsy Association; American Neurological Association; American ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HLA Histocompatibility Antigens
Ipa Invasion plasmid antigens
MHC Major histocompatibility antigens
MAA Melanoma-associated antigens
MiHA Minor histocompatibility antigens
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ABO blood group system
    ABO Ç÷¾×Çü°è, ABO Ç÷¾×Çü °èÅë
    A, B´Â ¿ì¼º, O´Â ¿­¼ºÀ¸·Î¼­, A, B, AB, OÇüÀÌ ÀÖ´Ù.
  • allyl group
    ¾Ë¸±±º
  • axon group
    Ãà»è ±º
  • blood group
    Ç÷¾×Çü
    µ¿ÀǾî=blood ty
  • blood group incompatibility
    Ç÷¾×Çü ºÎÀûÇÕ
  • borderline group
    °æ°è ±º
  • chloramphenicol group antibiotics
    Ŭ·Î¶÷Æä´ÏÄݱº Ç×»ýÁ¦
  • coxsackie group A virus
    ÄÛ»èŰ A±º ¹ÙÀÌ·¯½º
    ¼öÆ÷¼º º´º¯ÀÎ Æ÷Áø¼º ±¸Çù¿°À» ¹ß»ý ½ÃŲ´Ù.
  • Coxsackie virus group A
    A±º ÄÛ»çŰ ¹ÙÀÌ·¯½º
  • E-blood group
    ÀÌ½Ä Ç÷¾×Çü
    »ç¶÷ÀÇ Ç÷¾×ÇüÀÇ Çϳª. OÇü ÀÌ¿ÜÀÇ Ç÷¾×ÇüÀ» °¡Áø »ç¶÷ Áß¿¡¼­ ¹ìÀå¾îÀÇ Ç÷û ¼Ó¿¡ Á¸ÀçÇÏ´Â ÀÀÁý¼Ò¿¡ °­ÇÏ°Ô ¹ÝÀÀÇÏ´Â °ÍÀ» EÇü, ¹ÝÀÀÀÌ ¾àÇÑ °ÍÀ» eÇüÀ¸·Î ÇÏ´Â Ç÷¾×ÇüÀ» ¸»ÇÑ´Ù. EÇüÀº ABO½ÄÀÇ BÇü¿¡ °¡Àå ¸¹°í, A, AB ¼øÀ¸·Î ºóµµ°¡ ³·´Ù. ¶ÇÇÑ À¯ÀüÀÚÇü°úµµ °ü°è°¡ ÀÖÀ¸¸ç II, II
  • herpes group of virus
    Æ÷Áø¼º ¹ÙÀÌ·¯½º
  • high risk group
    °íÀ§Çèµµ±º
  • Lutheran blood group
    ·çÅ×¶õ½Ä Ç÷¾×Çü
    Ç÷¾×ÇüÀÇ ÀÏÁ¾. ¿ì¿­ÀÌ ¾ø´Â ÇÑ ½ÖÀÇ ´ë¸³ À¯ÀüÀÚ Lu, Lu¿¡ ÀÇÇØ¼­ Áö¹èµÇ°í, ÀÌ À¯ÀüÀÚÀÇ Á¶ÇÕ¿¡ µû¶ó¼­ »ç¶÷ÀÇ Ç÷±¸´Â Lu
  • methyl green-pyronin of nucleolus

    methyl group

    ¸ÞÄ¥±â
  • myelinated group
    À¯¼öÃʱº
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
group antigens Antigen's that are shared by related genera of microorganisms.
(05 Mar 2000)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
MN blood group antigens <haematology, immunology> A pair of blood group antigens governed by genes that segregate independently of the ABO locus. The alleles are codominant and there are three types MM, NN and MN. Glycophorin has M or N activity and this is associated with oligosaccharides attached to the amino terminal portion of the molecule. M type glycophorin differs from N type in amino acid residues 1 and 5, although the antigenic determinants are associated with the carbohydrate side chains.
(18 Nov 1997)
ABO antigens <haematology, immunology> A system of genetically determined antigens (proteins) located on the surface of the erythrocyte.
The presence of these specific antigens gives a blood its unique properties. Because of the antigen differences existing between individuals, blood groups are significant in blood transfusions, maternal-foetal incompatibilities (erythroblastosis foetalis), tissue and organ transplantation.
(27 Sep 1997)
Am antigens Allotypic determinants (antigens) on human immunoglobulin alpha heavy chains.
(05 Mar 2000)
antigens Substances which are capable, under appropriate conditions, of inducing a specific immune response and of reacting with the products of that response, that is, with specific antibodies or specifically sensitised T-lymphocytes, or both. Antigens may be soluble substances, such as toxins and foreign proteins, or particulates, such as bacteria and tissue cells; however, only the portion of the protein or polysaccharide molecule known as the antigenic determinant (epitopes) combines with antibody or a specific receptor on a lymphocyte.
(12 Dec 1998)
antigens, archaeal Substances of archaeal origin that have antigenic activity.
(12 Dec 1998)
antigens, bacterial Substances elaborated by bacteria that have antigenic activity.
(12 Dec 1998)
antigens, CD <immunology> Differentiation antigens residing on human leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similiar reactivity with certain subpopulations of antigens. The subpopulations of antigens are also known by the same CD designation.
(12 Dec 1998)
antigens, CD1 <immunology> Glycoproteins expressed on cortical thymocytes and on some dendritic cells and B-cells. Their structure is similar to that of MHC class I and their function has been postulated as similar also. Cd1 antigens are highly specific markers for human langerhans cells.
(12 Dec 1998)
antigens, CD11 <immunology> A group of three different alpha chains (CD11a, CD11b, CD11c) that are associated with an invariant CD18 beta chain (antigens, CD18). The three resulting leukocyte-adhesion molecules (receptors, leukocyte adhesion) are lymphocyte function-associated antigen-1, macrophage-1 antigen, and antigen, p150,95.
(12 Dec 1998)
antigens, CD13 <enzyme, immunology> Glycoproteins expressed on human granulocyte-monocyte progenitor colony forming units (cfu-gm) and their more differentiated progeny. The enzymes are also found in a large number of tissues, often associated with membranes.
Registry number: EC 3.4.11.2
(12 Dec 1998)
antigens, CD14 <immunology> Glycolipid-anchored membrane glycoproteins expressed on cells of the myelomonocyte lineage including monocytes, macrophages, and some granulocytes. They function as receptors for the complex of lipopolysaccharide (lps) and lps-binding protein.
(12 Dec 1998)
antigens, CD15 <immunology> Carbohydrate antigen which is accumulated in various human cancer tissues and secreted into the blood stream. The carbohydrate moiety can be further modified with fucose or sialic acid. Monoclonal antibodies have been determined which can discriminate each subgroup of this antigen in the sera of cancer patients. Sialyl ssea-1 antigen is particularly elevated in the sera of patients with a variety of tumours.
(12 Dec 1998)
antigens, CD18 <immunology> Cell-surface glycoprotein beta-chains that are non-covalently linked to specific alpha-chains of the CD11 family of leukocyte-adhesion molecules (receptors, leukocyte-adhesion). A defect in the gene encoding CD18 causes leukocyte-adhesion deficiency syndrome.
(12 Dec 1998)
antigens, CD19 <immunology> Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
(12 Dec 1998)
antigens, CD2 <immunology> Glycoprotein members of the immunoglobulin superfamily which participate in T-cell adhesion and activation. They are expressed on most peripheral T-lymphocytes, natural killer cells, and thymocytes, and function as co-receptors or accessory molecules in the T-cell receptor complex.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • age-group
    ¿¬·É Áý´Ü
  • group
    Áý´Ü,¶¼¸¦ Áþ´Ù,ºÐ·ùÇÏ´Ù
  • Group of 77
    77°³±¹ ±×·ì(UNÀÇ ¹«¿ª°³¹ß ȸÀÇ(UNCTAD)ÀÇ È¸¿øÀÎ ¹ßÀü µµ»ó±¹ ±×·ì)
  • Group of Seven
    G;7 ¼±Áø 7°³±¹ ±×·ì
  • blood group
    Ç÷¾×Çü Á¤
  • code group
    ºÎÈ£±º
  • continuous group
    ¿¬¼Ó±º
  • control group
    Á¦¾îÁý´Ü;Á¶Á¾ÀåÄ¡;´ëÁ¶±º(µ¿ÀϽÇÇè¿¡¼­ ½ÇÇè¿ä°ÇÀ» °¡ÇÏÁö ¾ÊÀº ±×·ì)
  • enxounter group
    (Á¤ÀÇ)Áý´Ü °¨¼ö¼º ÈÆ·Ã ±×·ì
  • ethnic group
    (»çȸ)ÀÎÁ¾ Áý´Ü
  • focus group
    Æ÷Ä¿½º ±×·ì(Å×½ºÆ®ÇÒ »óǰ¿¡ ´ëÇØ¼­ ÅäÀÇÇÏ´Â ¼ÒºñÀÚ ±×·ì)
  • fringe group
    ºñÁÖ·ùÆÄ
  • front group
    (À§ÀåÇÑ) Ç¥¸é»óÀÇ Á¶Á÷(´Üü)
  • ginger group
    (Á¤´ç µûÀ§ Á¶Á÷ ³»ºÎÀÇ)Çõ½ÅÆÄ
  • group
    ¹«¸®;ºñÇà ´ë´ë;ºñÇà ¿¬´ë
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á